What is the current market price of pirtobrutinib and is it worth buying?

Pirtobrutinib, as a new type of BTK inhibitor, has shown good efficacy and tolerability in the treatment of various hematological malignancies in recent years. In 2025, pitobrutinib has been officially launched in China. However, due to the short launch time, patients still have certain difficulties in purchasing it directly in the country, especially in some areas where the drug supply is not yet fully popular.

In overseas markets, the original research version of pitobrutinib mainly includes the European version and the American version. These versions are relatively expensive, with the latest selling price being about 100,000 yuan. The high price puts many patients under greater financial pressure, affecting their long-term treatment compliance and medication choices.

In order to reduce the burden on patients, the Lao Ministry of Health approved a generic version of pitobrutinib produced by Lucius Pharmaceuticals. The specification of this generic drug is 50mg*30 tablets, and the price is less than 3,000 yuan, which is far lower than the price of the original drug. Generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, providing patients with limited economic conditions with a more user-friendly medication option.

Taken together, although pitobrutinib has been launched in China, there is still a certain threshold for purchase at this stage. Patients can consider choosing overseas original drugs or Laotian generic drugs based on their own circumstances and financial capabilities, combined with doctor's advice. With the improvement of the supply chain and policy support, the accessibility and cost-effectiveness of pitobrutinib will continue to improve in the future.

Reference materials:https://www.drugs.com/